You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

blinatumomab

( blin-a-too-moo-mab )
Funding:
New Drug Funding Program
  • Blinatumomab – Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia
  • Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)
  • Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph- BCP-ALL)
Other Name(s): Blincyto®
Appearance: solution mixed into larger bags of fluids

You might also be interested in